Apimeds Pharmaceuticals US, Inc (APUS) Research

Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.

Market snapshot

Symbol
APUS
Price
$1.09
Day change
-16.79%
Market cap
$1.4M
P/E ratio
-0.42x
52-week range
1.075-40.31
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • AN2 Therapeutics, Inc. (ANTX)
  • IGC Pharma, Inc. (IGC)
  • MIRA Pharmaceuticals, Inc. (MIRA)
  • Milestone Scientific Inc. (MLSS)
  • Myomo, Inc. (MYO)
  • NextCure, Inc. (NXTC)
  • Precision Optics Corporation, Inc. (POCI)
  • Q32 Bio Inc. (QTTB)

Recent insider activity

  • Inscobee Inc. — trade (0 shares) on 2024-05-12
  • Weintraub Bennett — A-Award (10000 shares) on 2025-11-11
  • Yoon Hankil — A-Award (10000 shares) on 2025-11-11
  • Koo Jakap — A-Award (10000 shares) on 2025-11-11
  • O'DONNELL CAROL A — A-Award (10000 shares) on 2025-11-11

Open Apimeds Pharmaceuticals US, Inc (APUS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.